At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
RNXT RenovoRx Inc
Post-Market Trading 01-08 18:23:14 EST
1.32
-0.05
-3.65%
盘后1.38
+0.06+4.48%
16:42 EST
High1.44
Low1.32
Vol45.62K
Open1.43
D1 Closing1.37
Amplitude8.75%
Mkt Cap31.66M
Tradable Cap31.06M
Total Shares23.99M
T/O61.28K
T/O Rate0.19%
Tradable Shares23.53M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
RenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025
RenovoRx Initiates Patient Enrollment at Scri Oncology Partners for Ongoing Pivotal Phase Iii Tiger-Pac Clinical Trial in Locally Advanced Pancreatic Cancer
RenovoRx Initiates Patient Enrollment at SCRI Oncology Partners for Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial in Locally Advanced Pancreatic Cancer
RenovoRx Increases Production of FDA-Cleared Renovocath® Delivery System in Response to Strong Demand From Oncology and Interventional Radiology Physicians
RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians
RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting Tamp™ for Targeted Treatment of Locally Advanced Pancreatic Cancer
RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.